Skip to main content

Table 1 Breast cancer subtype characterization and immune-related reclassification

From: Mechanisms of immune evasion in breast cancer

Molecular Subtype Gene expression pattern Clinical features Common treatment options Potential reclassification
Luminal A ER+ and/or PR+, HER2, and low Ki67 30–70% prevalence;
Tumor grade of 1 or 2
Endocrine therapy;
Aromatase inhibitors;
Standard chemotherapy;
Best prognosis of the four tumor types
Further research required
Luminal B ER+ and/or PR+ and HER2+ or –;
High Ki67
10–20% prevalence;
Often younger age of diagnosis;
Higher grade and worse prognosis than luminal A
Endocrine therapy; Aromatase inhibitors;
Standard chemotherapy
Further research required
HER-2-enriched ER, PR, and HER2+ 5–15% prevalence; Likely to be high grade and LN+; Poor prognosis Trastuzumab; Pertuzumab; T-DM1; lapatinib; TKIs; anthracycline-based chemotherapy SR +/−; CC +/−; IR +/−; ECM +/− (Teschendorff et al. [22]); (Staaf et al. [21])
Triple negative/basal-like ER, PR, HER2 15–20% prevalence;
High grade and proliferation;
Often BRCA-1 related;
Radiation; Platinum-based chemotherapy; PARP inhibitors CC +/−; IR +/−; ECM +/− (Teschendorff et al. [22]);
BL1, BL2, IM, MSL, LAR (Lehmann et al. [23])
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, SR steroid hormone response, CC cell cycle, IR immune response, ECM extracellular matrix, BL1 and 2 Basal-like 1 and 2, IM immunomodulatory, MSL mesenchymal stem-like, LAR luminal androgen receptor, LN lymph node